Answers are grounded in this paper and cite their sources.
Case studies on pesticide exposure and endocrine disruptors reveal insights into risk assessment methodologies, suggesting improvements for regulations.
Two case studies, (1) Parkinson's disease and pesticide exposure, and (2) exposure to substances with endocrine-disrupting properties and the development of uterine adenocarcinoma, are described. The analysis of the entire AOP construct for each case and the assembly of the specific NAMs allowed us to identify the strengths and limitations of the AOP strategy, as well as of each proposed test. Their integration and status are assessed within the current regulatory framework.
No takes yet. Share an insight, caveat, or question.
D'Amore et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: